Michael Smylie

Contact

Faculty of Medicine & Dentistry - Oncology Dept
Email
msmylie@ualberta.ca
Phone
(780) 432-8757
Address
Cross Cancer Institute
11560 University Avenue
Edmonton AB
T6G 1Z2

Overview

Area of Study / Keywords


About

Dr. Michael Smylie is currently appointed as Professor in the Department of Oncology in the Faculty of Medicine & Dentistry.

Research

Melanoma and Lung Cancers

  • Site Leader – Clinical Trials Committee – Cross Cancer Institute NCIC Melanoma Group Leader and very active in designing and participating in malignant melanoma.
  • Targeted therapy and new drug development in metastatic melanoma.
  • He has chaired several National Melanoma Meetings and organized the past three National Melanoma Conferences in Canada.
  • Chair – Mary Johnston Professorship in Melanoma Research – 2006-2007. This is a $1,000,000 donation from the Mary Johnston family and the Alberta Government through their endowment fund has guaranteed to match this contribution dollar for dollar. In recognition of this patient and her family, Cross Cancer Institute has created the endowed Mary Johnston Professorship in melanoma research. In October of 2007, Dr. Alan Underhill, Department of Medical Genetics of the University of Alberta took over the Chair Position of this Professorship. Dr. Underhill and Dr. Smylie are keen in objectives in basic research to identify targets in melanoma. This is the first research in this field in Canada.

 

Featured Publications

Hung W., Cusnir I., Habib S., Smylie M., Solez K., Yacyshyn E.

Rheumatology (United Kingdom). 2021 June; 60 (6):E190-E191 10.1093/rheumatology/keaa818


ASCO 2021. 2021 May; 10.1200/JCO.2021.39.15_suppl.9506


ASCO 2021. 2021 May; 10.1200/JCO.2021.39.15_suppl.9516


Youn S., Reif R., Chu M.P., Smylie M., Walker J., Eurich D.T., Ghosh S., Sawyer M.B.

Clinical Nutrition ESPEN. 2021 April; 42 10.1016/j.clnesp.2021.01.009


Hodi F.S., Chapman P.B., Sznol M., Lao C.D., Gonzalez R., Smylie M., Daniels G.A., Thompson J.A., Kudchadkar R., Sharfman W., Atkins M., Spigel D.R., Pavlick A., Monzon J., Kim K.B., Ernst S., Khushalani N.I., Van Dijck W., Lobo M., Hogg D.

Melanoma Research. 2021 February; 10.1097/CMR.0000000000000708


AlZahrani F., Kuzel P., Metelitsa A., Smylie M., Dover D., Fiorillo L.

Journal of Cutaneous Medicine and Surgery. 2020 October; 25 (2):133-141 10.1177/1203475420963658


Hogg D., Monzon J.G., Savage J., Skinn B., Ernst S., Song X., McWhirter E., Romeyer F., Smylie M.

Current Oncology. 2020 August; 27 (4):204-214 10.3747/co.27.5985


Ascierto P.A., Del Vecchio M., Mackiewicz A., Robert C., Chiarion-Sileni V., Arance A., Lebbé C., Svane I.M., Mcneil C., Rutkowski P., Loquai C., Mortier L., Hamid O., Bastholt L., Dreno B., Schadendorf D., Garbe C., Nyakas M., Grob J.J., Thomas L., Liszkay G., Smylie M., Hoeller C., Ferraresi V., Grange F., Gutzmer R., Pikiel J., Hosein F., Simsek B., Maio M.

Journal for ImmunoTherapy of Cancer. 2020 June; 8 (1) 10.1136/jitc-2019-000391


Chu M.P., Li Y., Ghosh S., Sass S., Smylie M., Walker J., Sawyer M.B.

Journal of Cachexia, Sarcopenia and Muscle. 2020 June; 11 (3):748-755 10.1002/jcsm.12538


Journal of Clinical Oncology. 2020 May; 10.1200/JCO.2020.38.15_suppl.10019


Suo A., Chan Y., Beaulieu C., Kong S., Cheung W.Y., Monzon J.G., Smylie M., Walker J., Morris D., Cheng T.

Oncologist. 2020 May; 25 (5):438-446 10.1634/theoncologist.2019-0674


Smylie M.G.

Current Oncology. 2020 January; 27 (S2):51-58 10.3747/co.27.5135


Ganesan A., Ahmed M., Okoye I., Arutyunova E., Babu D., Turnbull W.L., Kundu J.K., Shields J., Agopsowicz K.C., Xu L., Tabana Y., Srivastava N., Zhang G., Moon T.C., Belovodskiy A., Hena M., Kandadai A.S., Hosseini S.N., Hitt M., Walker J., Smylie M., West F.G., Siraki A.G., Lemieux M.J., Elahi S., Nieman J.A., Tyrrell D.L., Houghton M., Barakat K.

Scientific Reports. 2019 December; 9 (1) 10.1038/s41598-019-48826-6


Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D., Cowey C.L., Schadendorf D., Wagstaff J., Dummer R., Ferrucci P.F., Smylie M., Hogg D., Hill A., Márquez-Rodas I., Haanen J., Guidoboni M., Maio M., Schöffski P., Carlino M.S., Lebbé C., McArthur G., Ascierto P.A., Daniels G.A., Long G.V., Bastholt L., Rizzo J.I., Balogh A., Moshyk A., Hodi F.S., Wolchok J.D.

New England Journal of Medicine. 2019 October; 381 (16):1535-1546 10.1056/NEJMoa1910836


Annals of Oncology. 2019 October; 10.1093/annonc/mdz255


LBA68_PR - 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

Annals of Oncology. 2019 September;